FDA Accepts Recros Medica De Novo Submission for Nuvellus Focal Contouring System

Recros Medica, Inc. announced today that its de novo regulatory submission for the Nuvellus™ Focal Contouring System has been accepted for review by the US Food and Drug Administration (FDA). Nuvellus™, which utilizes the company’s proprietary Rotational Fractional Resection (RFR) technology, may provide medical aesthetic physicians a minimally-invasive single treatment option to improve submental (neck and jowl) contouring.

CONFORM Clinical trial poster

Efficacy, Safety, and Subject Satisfaction Using Rotational Fractional Resection for the Improvement of Submental Contouring. By Steve Dayan, MD; Jill Waibel, MD; Steve Yoelin, MD CONFORM clinical trial poster

Recros Medica Showcases Interim Data on Rotational Fractional Resection Technology at 2018 ASDS

SAN DIEGO, Oct. 9, 2018 /PRNewswire/ -- Recros Medica, Inc. announced today it will showcase its Rotational Fractional Resection (RFR) platform at the 2018 American Society for Dermatologic Surgery Annual Meeting. This investigational technology which is being developed as the Nuvellus™ Focal Contouring System for use by dermatologists, plastic surgeons and other aesthetic physicians to reduce skin laxity and remove Read more

This website uses cookies and third party services. Ok